Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
View original at globenewswire.comTempest Reports First Quarter 2026 Financial Results and Provides Business Update Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as Lead Ma…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
100% complete response (CR) rate was observed among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 across the REDEEM-1 and POEMS-1 trials
60% confidenceThe $7.5M decrease in R&D expenses in Q1 2026 vs Q1 2025 was primarily due to a decrease in costs from re-prioritizing efforts towards exploring strategic alternatives initiated in April 2025 and resulting in the Asset Acquisition completed in February 2026
60% confidence44 patients with relapsed/refractory multiple myeloma have been treated with TPST-2003 to date across three studies
60% confidenceTPST-2003 demonstrated a favorable safety profile with no Grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) in the REDEEM-1 trial, which appears to be emerging as a potentially differentiating attribute in its class
60% confidenceThe prior investigator-initiated trial (IIT) of TPST-2003 reached a median progression free survival (PFS) of 23.1 months, including in patients with extramedullary disease
60% confidenceAndrew Fang's appointment as Head of Business Development, with a focus on strategic partnerships, licensing, and corporate transactions including China outreach, will help position Tempest for long-term growth
60% confidenceA biologics license application (BLA) filing in China for TPST-2003 is planned for 2027, funded by a strategic partner
60% confidenceTempest plans to initiate the first potentially registrational study to evaluate a dual-targeting CAR-T therapy in patients with rrMM, including patients with extramedullary disease, later in 2026
60% confidenceStrong progress was made in Q1 2026 as key activities supporting the planned U.S. registrational study of TPST-2003 in rrMM were advanced, including announcing AGCTC as lead manufacturing partner and taking delivery of the TPST-2003 lentiviral vector
60% confidenceThe $2.1M increase in G&A expenses in Q1 2026 vs Q1 2025 was primarily due to one-time costs resulting from the Asset Acquisition completed in February 2026
60% confidenceThe decrease in cash from $7.7M to $1.8M in Q1 2026 was primarily due to one-time transaction-associated costs from the Asset Acquisition, offset by $1.7M net proceeds from the 2026 Offering
60% confidence